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350with body mass index (BMI), and we acknowledge
concerns Krachler et al. mentioned regarding the
possible error in calculating METs in obese patients
during load-bearing exercise, in particular when
comparing normal weight patients with obese pa-
tients. However, in the CARDIO-FIT study, the mean
BMI was not different between the CRF groups at
baseline and could not have resulted in a selection or
ascertainment bias. We are therefore conﬁdent that, in
the absence of any between-group differences in BMI,
our study ﬁndings remain valid regardless of the
measurement used to score CRF.
Another seminal ﬁnding of the study was the effect
of CRF gain on AF outcome. Individuals who gained
CRF of$2METs had signiﬁcantly greater weight loss. A
previous study showed minor difference in the degree
of underestimation of peak METs for each 5-unit
change in BMI (3). In our study, the mean weight loss
in the $2 MET gain group was 3.9 kg/m2 and was un-
likely to have resulted in signiﬁcant alteration in
the MET measurement. A gain of $2 MET in CRF was
associated with 2-fold greater freedom from AF. This
gainwas above the beneﬁt conferred by theweight loss
alone in these patients, highlighting the prescriptive
role of exercise in managing patients with AF.
Finally, the CARDIO-FIT study emphasizes the
importance of incremental beneﬁt of gain in CRF
through a structured exercise program along with
weight-loss, on freedom from AF. The study does not
advocate a “ﬁtness ﬁrst approach.” Beneﬁt from the
“alliance of CRF with weight-loss” is truly over and
above the strategic gain provided by each individually.
Recent studies have demonstrated the beneﬁcial effect
of weight and risk factor management on long-term
freedom from AF (4,5). In summary, we strongly advo-
cate a multimodal approach to lifestyle modiﬁcation. A
structured exercise program to increase CRF should be
an integral component of the management strategy for
AF, particularly in the strategy of rhythm control.Rajeev K. Pathak, MBBS
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Risk Estimator App
From Concept to the Current StateInitial incorporation of the 2013 Blood Cholesterol
Guidelines (1) into clinical practice came with a
particular challenge. Providers were asked to assess
atherosclerotic cardiovascular disease (ASCVD) risk
by manually entering data into an electronic spread-
sheet, using the Omnibus Risk Estimator (2). Not only
was this an impractical solution for nearly all pro-
viders at the point of care, it also severely limited
patients’ ability to engage in risk assessment.
The solution was obvious, we needed a point-of-
care tool that would allow providers the ability to
easily calculate 10-year ASCVD risk, and although
such a stand-alone tool would certainly be valuable,
we recognized that this represented an opportunity to
do so much more. This, in essence, is the history of
the ASCVD risk estimator application software (app).
On February 10, 2014, the ASCVD risk estimator
was made available for free by the American
College of Cardiology and American Heart Associa-
tion, both on the internet and as an app on iTunes
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351and Google Play (Figure 1). To date, there have been
>3.9 million internet/app visits and over 240,000
app downloads. On average, it is used >11,000 times
each day.
Although the app has received positive feedback,
including being rated the bestmedical app byMedPage
in 2014 (3), there is room for improvement. Most
pressing for us is a desire to better inform individuals
that a predicted ASCVD risk of $7.5% should not
automatically lead to a statin prescription. Often
misunderstood, the guideline actually recommends
that these primary prevention patientsﬁrst enter into a
dialogue with their clinician about: 1) the anticipated
beneﬁts and potential adverse effects associated withFIGURE 1 Screenshots From the ASCVD Risk Estimator App
Screenshots from the ASCVD risk estimator app demonstrate (top left) ho
(bottom left) references for clinicians, and (bottom right) references for pstatin therapy; 2) the risk of drug-drug interactions; 3)
the importance of addressing other risk factors; and 4)
inclusion of an informed patient’s preference. This
clinician-patient risk discussion is an important ﬁrst
step in patient engagement and can be a powerful aid
to improve not only medical decision making but, if a
statin is chosen, medication adherence.
It is for these reasons that the app was recently
highlighted as an effective tool to implement shared
decision making (4). Simply put, the app is a decision
aid that can be used by patients and care providers,
either together during the clinical encounter or
separately between visits. Used appropriately, this
app empowers more patients to know their risk andw risk is estimated, (top right) recommendations based on ASCVD risk,
atients. ASCVD ¼ atherosclerotic cardiovascular disease.
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